NCT07093411View on ClinicalTrials.gov

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

December 31, 2028

Conditions
B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory
Interventions
BIOLOGICAL

LUCAR-E9D or LUCAR-E9K cells product

Prior to infusion of the LUCAR-E9D or LUCAR-E9K cells product subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine

Trial Locations (3)

Unknown

RECRUITING

The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei

RECRUITING

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

RECRUITING

Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

collaborator

Second Affiliated Hospital of Xi'an Jiaotong University

OTHER

collaborator

Anhui Provincial Hospital

OTHER_GOV

lead

Beijing GoBroad Hospital

OTHER